Introduction
============

COPD is a major public health problem and is expected to remain a challenge for health care systems well into the 21st century.[@b1-copd-12-2929] Despite falling death rates, COPD is still among the leading causes of death worldwide.[@b1-copd-12-2929] The disease burden associated with COPD is further exacerbated by the presence of comorbidities, which influence disease expression and survival.[@b2-copd-12-2929],[@b3-copd-12-2929] Pharmacotherapy is one of the principal approaches used in the management of COPD. Treatments for COPD can improve symptoms, health status, and exercise capacity, in addition to reducing the frequency and severity of exacerbations.[@b4-copd-12-2929] People with COPD are also highly likely to be prescribed multiple other therapies, to effectively combat their nonrespiratory comorbid conditions.[@b2-copd-12-2929] As a result, individuals with COPD may have complex medication regimens.[@b5-copd-12-2929],[@b6-copd-12-2929]

Complex pharmacotherapy is a key contributor to nonadherence,[@b7-copd-12-2929],[@b8-copd-12-2929] increased risk of drug--drug interactions and adverse drug events,[@b9-copd-12-2929] poor disease control,[@b10-copd-12-2929] and substantial cost of illness.[@b11-copd-12-2929] As Winner[@b12-copd-12-2929] pointed out, "the first step in minimizing complex medication regimens is to identify and quantify them." The medication regimen complexity index (MRCI) is a tool that has been developed and validated for this purpose.[@b5-copd-12-2929] MRCI measures the multiple aspects of medication regimens including type of dosage forms, dosing frequencies, and additional instructions that guide dosage administration.[@b5-copd-12-2929] The relationships between MRCI and clinical outcomes including quality of life,[@b13-copd-12-2929],[@b14-copd-12-2929] unplanned hospitalization,[@b15-copd-12-2929] all-cause mortality,[@b16-copd-12-2929] rehospitalization for adverse drug events,[@b9-copd-12-2929] and risk of hospital readmissions and/or emergency visits[@b17-copd-12-2929]--[@b19-copd-12-2929] have been investigated. Although MRCI was originally developed and validated in people with COPD,[@b5-copd-12-2929] so far only a few studies have applied this tool in studies involving COPD population.[@b17-copd-12-2929]--[@b19-copd-12-2929] Nevertheless, these studies as such did not specifically investigate the relationships of MRCI with COPD-related clinical outcomes and other dimensions of the disease.

The present study aimed to explore the associations of medication burden in COPD patients, as measured by medication count and MRCI, with COPD outcomes (including disease severity, disease-specific health-related quality of life, exercise capacity, and prior year COPD exacerbation and hospitalization history) and multidimensional prognostic indices. Furthermore, we sought to determine the contributions of comorbid conditions to complex medication regimens in COPD. The two hypotheses we tested were that, 1) MRCI would be associated with COPD disease severity and comorbidities, and 2) MRCI may potentially serve as an alternative tool to the existing comorbidity-specific indices and other multidimensional COPD indices.

Methods
=======

Study design and participants
-----------------------------

This study was a cross-sectional study involving 222 COPD patients (postbronchodilator forced expiratory volume in 1 second \[FEV~1~\] to forced vital capacity \[FVC\] ratio \<0.70).[@b4-copd-12-2929] The data for 72 participants were obtained from our previously published studies.[@b20-copd-12-2929],[@b21-copd-12-2929] The remaining 150 participants were recruited from the respiratory ambulatory care clinics at John Hunter Hospital (Newcastle, Australia), the clinical research databases of the Priority Research Centre for Healthy Lungs at the University of Newcastle and the Hunter Medical Research Institute (Newcastle, Australia), and through community advertisement. All participants provided written informed consent, and ethics approval was obtained from the Human Research Ethics Committee of the Hunter New England Local Health District (12/12/12/3.06) and the University of Newcastle (H-2013-0010).

Clinical assessment
-------------------

Participants attended up to two visits and demographic information, lung function, smoking history, medical history, medication use, dyspnea (modified Medical Research Council \[mMRC\] scale),[@b22-copd-12-2929] self-reported prior year exacerbation and hospitalization history, and health-related quality of life (St George's Respiratory Questionnaire \[SGRQ\][@b23-copd-12-2929] and COPD assessment test \[CAT\][@b24-copd-12-2929]) were recorded. Airflow limitation was assessed using spirometry (Medgraphics, CPFS/D USB™ Spirometer; BreezeSuite v7.1, Saint Paul, MN, USA) to measure pre- and postbronchodilator FEV~1~, FVC, and FEV~1~/FVC ratio. Severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification system of airflow limitation based on postbronchodilator FEV~1~% predicted (ie, GOLD grade 1, FEV~1~ ≥80%; GOLD grade 2, 50%≤ FEV~1~ \<80%; GOLD grade 3, 30%≤ FEV~1~ \<50%; GOLD grade 4, FEV~1~ \<30%).[@b4-copd-12-2929] Participants were evaluated using GOLD quadrants according to the 2011 GOLD "ABCD" assessment tool (using mMRC for symptom assessment).[@b4-copd-12-2929] Participants also performed a 6-minute walk test.[@b25-copd-12-2929]

Comorbidities
-------------

Comorbidities were recorded by interviewing participants using a medical history tool that examines 14 different body or organ systems. Participants were asked if they have any medical conditions relating to these organ systems. Self-reported comorbidity diagnosis was confirmed by reviewing patient's medical records or current medications list.

Exacerbation capture
--------------------

Exacerbation history was recorded by asking participants how many times in the last 12 months they experienced a COPD-related episode that led to hospitalization, emergency visit, or the need for oral corticosteroids and/or antibiotic for at least 3 days.

Comorbidity-specific and other multidimensional COPD indices
------------------------------------------------------------

Participants were evaluated using the following three comorbidity-specific indices, namely, Charlson Comorbidity Index (CCI),[@b26-copd-12-2929] comorbidity test (COTE),[@b27-copd-12-2929] and comorbidity, airway obstruction, dyspnea, and previous exacerbation (CODEx)[@b28-copd-12-2929] and four multidimensional indices, namely, body mass index, airflow obstruction, dyspnea and exercise capacity (BODE),[@b29-copd-12-2929] body mass index, airflow obstruction, dyspnea and severe exacerbations (BODEx),[@b30-copd-12-2929] age, dyspnea and airflow obstruction (ADO),[@b31-copd-12-2929] and dyspnea, airflow obstruction, smoking status and exacerbation (DOSE).[@b32-copd-12-2929] All indices were calculated as previously prescribed.[@b26-copd-12-2929]--[@b32-copd-12-2929]

Medication assessment and MRCI scoring
--------------------------------------

Complexity of medication regimens was quantified using the MRCI developed and validated by George et al.[@b5-copd-12-2929] MRCI is the summation of individual component scores for dosage form (section A), dosing frequency (section B), and medication administration instructions (section C). Higher MRCI scores indicate greater regimen complexity.[@b5-copd-12-2929]

Participants' current prescription and nonprescription COPD and non-COPD medication lists were reviewed, and MRCI scores were calculated using the University of Colorado's electronic MRCI Data Capture Tool[@b33-copd-12-2929] and its accompanying MRCI additional instructions document.[@b34-copd-12-2929] Akin to the suggestions of Abou-Karam et al,[@b18-copd-12-2929] if recommendations in the MRCI additional instructions were different from those described in the original MRCI article,[@b5-copd-12-2929] scoring was conducted in accordance with the latter. For situations where no guidance for scoring was provided in either MRCI additional instructions or the original MRCI article, working guidelines were developed by the authors (MRCI weighting score of 3 for Respimat^©^ and continuous positive airway pressure).

Statistical analysis
--------------------

Data were analyzed using Stata 13 (StataCorp LP, College Station, TX, USA) and were reported as mean (SD) or median (interquartile range \[*q*1, *q*3\]) depending on the distribution. Wilcoxon rank-sum test was used to compare medication counts, total MRCI scores, and MRCI sub-scores between COPD and non-COPD medications. Comparison of categorical data was performed using Fisher's exact test. Spearman's rank correlation coefficient was used to examine the associations of medication count and regimen complexity with clinical outcomes and multidimensional indices. The differences in total medication counts and total MRCI scores for all medications in patients with and without a given class of comorbidity were assessed using either Student's *t*-test (for normally distributed data) or Wilcoxon rank-sum test (for skewed data). Using the class of comorbidities that resulted in statistically significant differences in medication counts or MRCI scores in the abovementioned comparison analyses, we performed multiple regression analyses, adjusting for age and sex, to identify which classes of comorbidities individually contributed to higher medication counts and complex medication regimens. Prior to fitting the regression models, multicollinearity of variables was assessed using the variance inflation factor (VIF), which measures how much the variance of an estimated regression coefficient increases if predictors are correlated. A VIF score of between 5 and 10 is often taken as an indication that multicollinearity may be overly influencing the least squares estimates.[@b35-copd-12-2929] Kruskall--Wallis test was performed to compare medication counts and MRCI scores in patients grouped in the different GOLD grades and quadrants. All results were reported as significant when *P*\<0.05.

Results
=======

Cohort characteristics
----------------------

Participants (58.6% males) had a mean (SD) age of 69.1 (8.3) years and mild-to-severe airflow limitation ([Table 1](#t1-copd-12-2929){ref-type="table"}). Over one-third (38%) of participants were GOLD grade 3 or higher, and over half (52.7%) were in GOLD quadrant D. Participants had significantly impaired health-related quality of life, with mean (SD) CAT and SGRQ scores of 20.6 (6.9) and 54.1 (16), respectively.

Comorbidities
-------------

A total of 118 comorbidities were recorded. The number of comorbidities per participant ranged from 0 to 11 with a median (*q*1, *q*3) of 5 (3, 7). [Figure 1](#f1-copd-12-2929){ref-type="fig"} shows the prevalence of comorbidities by disease categories. The prevalence of individual comorbidities is provided in [Table S1](#SD1-copd-12-2929){ref-type="supplementary-material"}.

Medication count and MRCI
-------------------------

[Table 2](#t2-copd-12-2929){ref-type="table"} presents medication counts and MRCI scores. The percentage contributions of dosage form (section A), dosing frequency (section B), and dosage instructions (section C) to the total MRCI scores of COPD, non-COPD, and all medications are shown in [Figure 2](#f2-copd-12-2929){ref-type="fig"}. The median (*q*1, *q*3) total MRCI score for all medications was 24 (18.5, 31). Nearly half of the participants (47.8%) were taking nine or more medications. Even though participants were taking a higher number of non-COPD medications compared to COPD-specific medications (median of 5 versus 3, respectively; *P*\<0.0001), the latter had greater complexity (median total MRCI score: 14.5 versus 9; *P*\<0.0001) ([Table 2](#t2-copd-12-2929){ref-type="table"}). MRCI section A sub-score (dosage form) was the greatest contributor to total MRCI score of COPD medications accounting for 62.1% ([Figure 2](#f2-copd-12-2929){ref-type="fig"}) and was significantly greater than that for non-COPD medications (9 \[7, 10\] versus 2 \[1, 3\], respectively; *P*\<0.0001) ([Table 2](#t2-copd-12-2929){ref-type="table"}). MRCI section A quantifies complexity associated with using different dosage forms and may serve as a measure of inhaler device polypharmacy for the COPD medications we considered. In this study, 68 (30.6%) participants had three or more different inhaler devices prescribed concurrently. In the case of non-COPD medications, MRCI section B sub-score (dosing frequency) primarily drove the total MRCI score accounting for 66.7% ([Figure 2](#f2-copd-12-2929){ref-type="fig"}).

Comparisons of medication counts and regimen complexity based on GOLD quadrants and GOLD grades
-----------------------------------------------------------------------------------------------

When considering all medications, participants in GOLD quadrant D had significantly higher total MRCI score compared to those in quadrant A (*P*=0.0004) ([Figure 3](#f3-copd-12-2929){ref-type="fig"}). With regard to COPD-specific medications, participants in GOLD quadrant D had significantly higher total MRCI scores compared to those in GOLD quadrants A (*P*=0.0001) and B (*P*\<0.0001) ([Figure 3](#f3-copd-12-2929){ref-type="fig"}). Furthermore, both sections A (dosage form) and B (dosing frequency) sub-scores of the total MRCI score of COPD medications were significantly higher for participants in GOLD quadrant D (10 \[7, 10\] and 4.5 \[3.5, 6.5\], respectively) compared to those in GOLD quadrants A (7 \[6, 10\], *P*=0.003 and 3.5 \[2, 4.5\], *P*=0.0003, respectively) and B (7 \[7, 10\], *P*=0.001 and 3.5 \[2.5, 4\], *P*\<0.0001, respectively). Higher usage of nebulizer or oxygen ([Table S2](#SD2-copd-12-2929){ref-type="supplementary-material"}) and the combined higher occurrences of "three times daily", "four times daily", "every 6 hours", and "oxygen use over 15 hours" in participants in GOLD quadrant D may partly be responsible for the aforementioned complexity of COPD-specific regimens in this group. Only GOLD quadrants D and B had significantly different MRCI section C sub-scores (dosage instructions) (3 \[1, 2\] and 2 \[1, 2\], respectively; *P*=0.002). Both non-COPD medication regimen complexity and medication counts (COPD, non-COPD, and all medications) were similar among the different GOLD quadrants ([Table S3](#SD3-copd-12-2929){ref-type="supplementary-material"}).

Our analysis also showed that participants in GOLD grade 4 were taking significantly higher number of COPD medications (median 4 \[3, 4\]) compared to those in GOLD grades 1 (median 3 \[2, 3\]; *P*\<0.0001) and 2 (median 3 \[2, 3\]; *P*=0.0002). In addition, participants in GOLD grades 4 (median MRCI 18 \[13.5, 21\]) and 3 (median MRCI 15.5 \[12.5, 19.5\]) were found to have more complex COPD medication regimens than their counterparts in GOLD grades 1 (median MRCI 12.5 \[9.5, 15.5\]; *P*\<0.0001) and 2 (median MRCI 13.5 \[11, 15.5\]; *P*=0.0002).

Associations between medication burden and COPD outcomes
--------------------------------------------------------

There was a weak but significant positive association between total MRCI score for all medications and CAT score, SGRQ, and prior year exacerbation history ([Table 3](#t3-copd-12-2929){ref-type="table"}). We found a significant negative association between total MRCI score for all medications and 6-minute walk distance (6MWD). There were weak but significant positive relationships between total medication count for all medications and SGRQ and exacerbation history in the previous 12 months. Total medication counts negatively correlated with 6MWD. In contrast, we found no significant relationship between total medication counts and CAT score ([Table 3](#t3-copd-12-2929){ref-type="table"}). Both total MRCI score and total medication counts for all medications (ie, COPD and non-COPD medications together) did not show any correlations with postbronchodilator FEV~1~% predicted and prior year hospitalization history.

With regard to COPD-specific medications, significant but weak positive correlations were found between total MRCI score for COPD drugs and CAT score, SGRQ, and preceding year exacerbation and hospitalization history. Increased complexity of COPD-specific treatments showed weak correlations with lower lung function and 6MWD ([Table 3](#t3-copd-12-2929){ref-type="table"}). Similarly, SGRQ, CAT score, and number of exacerbations in the previous 12 months correlated positively with the number of COPD medications. In contrast, correlation between number of COPD medications and number of hospitalizations in the previous 12 months was absent. Higher number of COPD medications correlated with lower lung function and 6MWD ([Table 3](#t3-copd-12-2929){ref-type="table"}).

Medication counts and regimen complexity in relation to class of comorbidities
------------------------------------------------------------------------------

In our study, total medication count for all medications was significantly higher for participants with comorbid cardiovascular diseases, gastrointestinal diseases, musculoskeletal conditions, metabolic disorders, respiratory diseases, psychiatric disorders, skin disorders, or neurological conditions compared to those without these conditions. Comorbid cancer did not contribute to higher total medication counts ([Table 4](#t4-copd-12-2929){ref-type="table"}).

With regard to medication regimen complexity, our preliminary analysis has shown that participants with comorbid cardiovascular diseases, gastrointestinal diseases, metabolic disorders, other respiratory conditions, psychiatric disorders, or neurological conditions tended to have significantly higher total MRCI scores for all medications compared to those without these conditions ([Table 4](#t4-copd-12-2929){ref-type="table"}). Further examination revealed that non-COPD medications primarily drove medication complexity in the cases of comorbid cardiovascular diseases, gastrointestinal diseases, other respiratory conditions, or neurological conditions ([Figure 4A](#f4-copd-12-2929){ref-type="fig"}). In contrast, both COPD and non-COPD medications significantly contributed to complex medication regimens in the cases of comorbid metabolic or psychiatric disorders ([Figure 4B](#f4-copd-12-2929){ref-type="fig"}). Comorbid musculoskeletal diseases, skin disorders, and cancer did not contribute to complex medication regimen.

In order to identify which categories of comorbid conditions individually contributed to higher medication counts or greater complexity of regimen, multiple regression analyses were performed with either total medication counts or total MRCI score for all medications as dependent variables, after adjusting for age and sex. Accordingly, cardiovascular diseases (*β*=2.381; 95% confidence interval \[CI\]: 1.360--3.403; *P*\<0.0001), gastrointestinal diseases (*β*=0.927; 95% CI: 0.014--1.841; *P*=0.047), and metabolic disorders (*β*=1.003; 95% CI: 0.068--1.939; *P*=0.036) were found to be the three classes of comorbidities that significantly contributed to higher total medication counts. The proportion of variance explained by the regression model of total medication count (*R*^2^) was 0.29 (*P*\<0.0001) ([Table 5](#t5-copd-12-2929){ref-type="table"}). Cardiovascular diseases (*β*=3.225; 95% CI: 0.565--5.885; *P*=0.018) were the only class of comorbidities that individually contributed to the regression model of medication complexity (overall model fit \[*R*^2^\]=0.18; *P*\<0.0001) ([Table 6](#t6-copd-12-2929){ref-type="table"}).

Associations between medication burden and clinical scores in COPD
------------------------------------------------------------------

The correlations between total MRCI score for all medications and each of the following multidimensional indices CCI, COTE, CODEx, BODE, BODEx, DOSE, and ADO, as well as total medication count and the before mentioned indices are summarized in [Table 7](#t7-copd-12-2929){ref-type="table"}. The comorbidity-specific indices CCI and COTE showed the highest degree of correlation with both total MRCI score and medication counts. Total MRCI score was significantly associated with each of the remaining five indices considered, whereas medication count was only weakly associated with CODEx.

Discussion
==========

The present study set out to explore the associations of medication burden, as measured by medication count and MRCI, with clinical outcomes, comorbidities, and clinical scores in COPD. While similar previous studies in COPD mainly investigated the relationships between medication count and clinical outcomes only,[@b36-copd-12-2929],[@b37-copd-12-2929] to the best of our knowledge, the present study is the first to describe the relationships of COPD outcomes, comorbidities, and multidimensional indices with medication burden beyond medication count.

Our findings have shown that complex medication regimens are associated with COPD disease severity and specific class of comorbidities. According to our data, COPD medication counts and regimen complexity significantly related to both GOLD grades and GOLD quadrants. For instance, participants in GOLD grades 4 (median MRCI 18) and 3 (median MRCI 15.5) were found to have significantly higher MRCI scores compared to those in GOLD grades 1 (median MRCI 12.5; *P*\<0.0001) and 2 (median MRCI 13.5; *P*=0.0002). Moreover, participants in GOLD grade 4 were prescribed higher number of COPD medications compared to their counterparts in GOLD grades 1 and 2. This finding is consistent with previous reports indicating similar associations between increase in number of respiratory medications with severity of airflow limitation based on FEV~1~% predicted[@b36-copd-12-2929] and GOLD grades.[@b37-copd-12-2929] Our study has also revealed that participants in GOLD quadrant D had the most complex COPD-specific pharmacotherapy in all the three aspects of MRCI, especially when compared with those in quadrants A and B, even though they were taking a similar number of COPD medications as participants in all the other GOLD quadrants. This suggests that complexity of pharmacotherapy goes beyond the number of prescribed medications and that MRCI is a tool that can differentiate the true nature of treatment complexity.

Higher usage of nebulizer (MRCI weightings: 5) or oxygen (MRCI weightings: 3) in participants in GOLD quadrant D ([Table S2](#SD2-copd-12-2929){ref-type="supplementary-material"}) may have partly contributed to the aforementioned complexity of COPD-specific regimens in this group, as they are among the least convenient dosage forms due to the relative degree of difficulty in their administrations.[@b5-copd-12-2929] In contrast, while no single dosing frequency was able to individually account for the higher MRCI section B score in patients in GOLD quadrant D, the combined higher occurrences of three times daily, four times daily, every 6 hours, and oxygen use over 15 hours may partly be responsible. Of note, the use of pressurized metered-dose inhaler with a spacer for bronchodilator therapy has been shown to be as effective as nebulizer therapy, at least in acute asthma.[@b38-copd-12-2929] In relation to this, the findings of the present study demonstrate how nebulizers increase complexity of medication regimens and add support to the conversion of therapy to inhaler devices. It is worth mentioning here that long-term noninvasive ventilation (NIV) is increasingly being employed in COPD patients, particularly in those with pronounced hypercapnia.[@b39-copd-12-2929] Unfortunately, however, data on the use of home NIV were not collected in our study. The absence of this data may potentially underestimate the overall burden of treatment, especially in the case of the severe COPD patients.

Our data also demonstrate significant but weak correlations of poor lung function, poor 6MWD, impaired health-related quality of life, and higher number of prior year exacerbations with both higher number and increased complexity of COPD-specific treatments. Similar associations between several clinical outcomes, including 6MWD, SGRQ score, and number of exacerbations in the previous 12 months with the number of respiratory medications in COPD patients, have been previously reported.[@b37-copd-12-2929]

Consistent with previous reports of Divo et al[@b27-copd-12-2929] and Vanfleteren et al,[@b40-copd-12-2929] participants in our study had a median of 5 (3, 7) comorbidities. As might be expected, the presence or absence of comorbid conditions can considerably influence the number of medications that patients take as well as the complexity of regimens.[@b12-copd-12-2929] Most but not all of the comorbidities we studied were found to relate to overall medication burden in COPD. Our results illustrated that having comorbid musculoskeletal diseases, skin disorders, or cancer may not lead to a more complex pharmacotherapy in COPD patients. One possible explanation for this finding could be that these comorbidities may have been managed surgically and/or by using other non-pharmacological approaches (eg, radiation therapy and physiotherapy), the treatment burden of which cannot be captured by MRCI. In contrast, total MRCI score for all medications was significantly higher for patients with comorbid cardiovascular diseases, gastrointestinal diseases, metabolic disorders, other respiratory conditions, psychiatric disorders, or neurological conditions compared to those without these conditions. Multiple regression analysis, with age and sex as confounding variables, revealed that the presence of a comorbid cardiovascular disease can contribute approximately two additional medications to total medication counts and lead to an increase in total MRCI score of 3.23. Conversely, all the remaining comorbidities failed to individually contribute to the total MRCI score and medication count with the exception of gastrointestinal diseases and metabolic disorders, which individually contributed one medication each to total medication counts. It should be noted here that only 18% of the variance in total MRCI score was explained by the regression model of medication complexity ([Table 6](#t6-copd-12-2929){ref-type="table"}), suggesting that other factors probably also contribute, for instance, the effects of two or more concurrently existing comorbidities. It would be worthwhile to further explore how the co-occurrence of different types of comorbidities could potentially impact the complexity of pharmacotherapy in COPD. Moreover, investigating the contributions of specific comorbid diseases to complex medication regimens in COPD may provide clinically important insights.

Further analysis has shown that the complexity of medication regimens associated with having comorbid cardiovascular diseases, gastrointestinal diseases, other respiratory conditions, or neurological conditions was largely due to multiple dosing frequencies of non-COPD medications ([Figures 2](#f2-copd-12-2929){ref-type="fig"} and [4A](#f4-copd-12-2929){ref-type="fig"} and B). Interestingly, in the case of comorbid metabolic and psychiatric disorders, however, the complexity of the medication regimen involved both COPD and non-COPD medications ([Figure 4B](#f4-copd-12-2929){ref-type="fig"}). While this finding may be indicative of more prevalent usage of respiratory medications in COPD patients with coexistent metabolic or psychiatric illnesses, further investigation is warranted.

In this study, we identified a weak relationship between medication regimen complexity and some of the currently available multidimensional indices that are widely used for the assessment or prognostication of COPD and its comorbidities ([Table 7](#t7-copd-12-2929){ref-type="table"}). Multidimensional indices are important in the management of COPD due to their ability to stratify and prognosticate.[@b41-copd-12-2929] Despite this, however, they have not been widely used outside the research setting. With this in mind, one of the objectives of this study was to determine whether MRCI (and/or medication count) could serve as alternative tool(s) that can easily be applied in clinical settings, given that clinicians routinely review patient's medications in their day-to-day practice. While MRCI related to multidimensional indices in our study, the strength of the relationships we observed would not justify the use of MRCI or medication count in place of the existing multidimensional indices. Nevertheless, as in the case of related previous studies,[@b12-copd-12-2929],[@b33-copd-12-2929] the present study has illustrated that MRCI is a valuable clinical tool that can provide an insight into several aspects of disease and medication burden, which can form the basis for informed decision making and comprehensive medication review.

It is interesting to note that participants in our study were taking a higher number of medications compared to both slightly younger (median 62.7 \[61.7, 63.8\] years)[@b42-copd-12-2929] and older (mean \[SD\] 73.7 \[8.9\] years)[@b36-copd-12-2929] COPD patients in other studies. In our cohort, the median total MRCI score for all medications was 24 (18.5, 31). This relatively high MRCI score is similar to what previous studies reported in people with COPD (mean \[SD\] 28.7 \[5\])[@b19-copd-12-2929] and other chronic diseases including geriatric depression (mean \[SD\] 25.4 \[11.7\]),[@b33-copd-12-2929] diabetes mellitus (mean \[SD\] 23 \[11.6\]),[@b33-copd-12-2929] chronic kidney disease (mean \[SD\] 22.4 \[10.2\]),[@b43-copd-12-2929] and HIV (median 21 \[12, 29\])[@b44-copd-12-2929] but lower than that reported in hospitalized COPD patients (mean \[SD\] 35.3 \[14.4\])[@b18-copd-12-2929] and elderly inpatients (≥65 years, mean \[SD\] 30.3 \[14\]).[@b45-copd-12-2929]

We found that COPD-specific medication regimens were significantly more burdensome than those of non-COPD medications despite the fact that patients were taking a fewer number of COPD medications compared to non-COPD ones. COPD medication complexity was largely driven by complex dosage formulations ([Figure 2](#f2-copd-12-2929){ref-type="fig"}). The concurrent use of multiple different types of inhaler devices was also prevalent in our study population with one out of three patients having inhaler device polypharmacy (IDP) (defined as the use of three or more different inhaler devices).[@b21-copd-12-2929],[@b46-copd-12-2929] In people with respiratory diseases, complex medication regimens and IDP could lead to unintentional nonadherence to treatment, suboptimal device technique, and poor disease control.[@b47-copd-12-2929],[@b48-copd-12-2929] IDP is a recognizable attribute of airways disease that can be rectified via medication review and device rationalization.[@b21-copd-12-2929],[@b46-copd-12-2929] Our findings suggest that MRCI is a tool that can potentially assist clinicians in this regard by serving as a risk assessment tool for identifying COPD patients who may benefit from simplification of a complex dosage regimen as originally intended by George et al.[@b5-copd-12-2929]

Conclusion
==========

This study illustrated that patients with COPD face dual disadvantages with medication regimen complexity as a result of, first, the complex dosage formulations of their COPD medications and, second, the multiple dosing frequencies of non-COPD medications they may take for their comorbid diseases. Clinicians need to carefully consider all aspects of the disease burden of COPD patients together with the multiple aspects of their pharmacotherapy to identify ways of reducing medication regimen complexity in order to improve treatment adherence, achieve better treatment outcomes, and reduce potential adverse drug events. Based on our findings, minimizing multiple dosing frequencies where possible, minimizing the use of nebulizers, reevaluating the use of inhaler devices, and/or opting for combination therapies can be suggested as ways of reducing the considerable burden of treatment in COPD patients. Future studies in this area could benefit from investigating the effects of modifying medication regimen complexity on clinically relevant outcomes such as adherence, patient satisfaction, health status, unplanned hospitalization, and adverse drug events. One of the important findings of the present study was that comorbidities play a significant role in driving medication complexity in COPD. Given that COPD patients commonly suffer from multiple comorbidities, the relative significance of individual comorbidities and their co-occurrences on medication regimen complexity in COPD deserves further investigation.

Supplementary materials
=======================

###### 

Prevalence of self-reported diagnosed comorbidities

  Comorbidity                                Prevalence
  ------------------------------------------ ------------
  Cardiovascular diseases                    
   Hypertension                              91 (41%)
   Coronary artery disease                   21 (9.5%)
   Atrial fibrillation                       21 (9.5%)
   Arrhythmia/bundle branch blocks           18 (8.1%)
   Ischemic heart disease                    14 (6.3%)
   Myocardial infarction                     11 (4.9%)
   Aortic valve disorders                    10 (4.5%)
   Congestive heart failure                  5 (2.3%)
   Stroke                                    4 (1.8%)
   Abdominal aortic aneurysm                 3 (1.4%)
   Low blood pressure                        2 (0.9%)
   Deep vein thrombosis                      2 (0.9%)
   Peripheral vascular disease               1 (0.5%)
  Other respiratory diseases                 
   Asthma                                    79 (35.6%)
   Obstructive sleep apnea                   26 (11.7%)
   Bronchiectasis                            15 (6.8%)
   Pulmonary hypertension                    4 (1.8%)
   Asbestosis                                4 (1.8%)
   Pulmonary embolism                        2 (0.9%)
   Pulmonary fibrosis                        1 (0.5%)
  Gastrointestinal diseases                  
   Gastroesophageal reflux disease           93 (41.9%)
   Gastric/duodenal ulcer                    13 (5.9%)
   Hernia                                    10 (4.5%)
   Diverticulitis                            8 (3.6%)
   Gall bladder removed                      5 (2.3%)
   Inflammatory bowel syndrome               4 (1.8%)
   Ulcerative colitis                        1 (0.5%)
   Crohn's disease                           1 (0.5%)
  Metabolic disorders                        
   Hyperlipidemia                            72 (32.4%)
   Diabetes                                  36 (16.2%)
   Osteoporosis                              24 (10.8%)
   Hypothyroidism                            15 (6.8%)
   Glucose intolerance                       5 (2.3%)
   Hyperthyroidism                           2 (0.9%)
  Psychiatric disorders                      
   Depression                                68 (30.6%)
   Anxiety                                   34 (15.3%)
   Psychosis                                 2 (0.9%)
   Bipolar                                   1 (0.5%)
   Adjustment disorder                       1 (0.5%)
  Cancer                                     
   Skin cancer                               16 (7.2%)
   Prostate cancer                           5 (2.3%)
   Breast cancer                             5 (2.3%)
   Leukemia                                  4 (1.8%)
   Tumor on ENT                              3 (1.4%)
   Ductal cell carcinoma                     1 (0.5%)
   Cervical cancer                           1 (0.5%)
   Meningioma                                1 (0.5%)
  Musculoskeletal diseases                   
   Arthritis                                 52 (23.4%)
   Osteoarthritis                            40 (18.0%)
   Osteopenia                                3 (1.4%)
   Joint issues/fibromyalgia                 2 (0.9%)
  Blood disorders                            
   Anemia                                    14 (6.3%)
   Iron/vitamin B or D deficiency            3 (1.4%)
   Hemochromatosis                           2 (0.9%)
   Thrombocytopenia                          1 (0.5%)
   High white blood cell count               1 (0.5%)
   Pseudo-von Willebrand disease             1 (0.5%)
  Urology                                    
   Reduced kidney function                   14 (6.3%)
   Incontinence                              12 (5.4%)
   Benign prostate hypertrophy               10 (4.5%)
   Kidney infection                          10 (4.5%)
   Gout                                      6 (2.7%)
   Kidney stone/hematuria                    6 (2.7%)
   Renal failure                             4 (1.8%)
   Frequent urination                        3 (1.4%)
   Prolapsed bladder                         1 (0.5%)
   Hyperuricemia                             1 (0.5%)
   Leaky bowel                               1 (0.5%)
  Hepatic and pancreatic                     
   Liver dysfunction/abnormal LFT            6 (2.7%)
   Fatty liver                               5 (2.3%)
   Pancreatitis                              2 (0.9%)
   Hepatitis                                 2 (0.9%)
   Liver cirrhosis                           1 (0.5%)
   Abscess in bile duct                      1 (0.5%)
  Reproductive                               
   Ovarian cyst                              3 (1.4%)
   Pelvic inflammatory disease               2 (0.9%)
   Prolapsed cervix/uterus                   2 (0.9%)
   Vaginal lesion                            1 (0.5%)
  ENT                                        
   Hay fever                                 23 (10.4%)
   Sinusitis                                 20 (9.0%)
   Other ENT                                 13 (5.9%)
   Nasal polyps                              6 (2.7%)
   Vocal cord dysfunction                    6 (2.7%)
   Rhinitis                                  5 (2.3%)
  Eye diseases                               
   Cataract                                  58 (26.1%)
   Glaucoma                                  3 (1.4%)
   Astigmatism                               2 (0.9%)
   Macular degeneration                      2 (0.9%)
   Retinal detachment                        2 (0.9%)
   Retinal vein thrombosis                   1 (0.5%)
  Neurological conditions                    
   Headache                                  11 (5.0%)
   Transient ischemic attack                 11 (5.0%)
   Other neurological conditions             10 (4.5%)
   Migraine                                  8 (3.6%)
   Tremors                                   4 (1.8%)
   Sciatica                                  3 (1.4%)
   Dementia                                  3 (1.4%)
   Stenosis                                  2 (0.9%)
   Motor neuron disease                      1 (0.5%)
   Epilepsy                                  1 (0.5%)
   Bulged disc                               1 (0.5%)
   Cerebral abscess                          1 (0.5%)
  Skin disorders                             
   Eczema                                    12 (5.4%)
   Easy bruising                             12 (5.4%)
   Dermatitis                                11 (5.0%)
   Psoriasis                                 9 (4.1%)
   Skin issues related with medication use   8 (3.6%)
   Skin thinning/itchiness                   6 (2.7%)
   Rashes                                    6 (2.7%)
   Dry skin                                  3 (1.4%)
   Sweet's syndrome                          1 (0.5%)
   Purpura                                   1 (0.5%)
   Athlete's foot                            1 (0.5%)
   Rosacea                                   1 (0.5%)
   Cellulitis                                1 (0.5%)
  Venous diseases                            
   Varicose vein                             2 (0.9%)

**Abbreviations:** ENT, ear, nose and throat; LFT, liver function test.

###### 

Use of nebulizer or oxygen in participants in different GOLD quadrants

  Nebulizer or oxygen use   GOLD quadrant A   GOLD quadrant B   GOLD quadrant C   GOLD quadrant D   Total
  ------------------------- ----------------- ----------------- ----------------- ----------------- -------
  No                        20                44                33                87                184
  Yes                       1                 5                 2                 30                38
  Total                     21                49                35                117               222

**Note:** Fischer's exact =0.005.

**Abbreviation:** GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Medication counts and MRCI scores of COPD, non-COPD, and all medications in GOLD quadrants

  Measures                                   GOLD quadrants   *P*-value                                                                                                                                              
  ------------------------------------------ ---------------- ------------------- --------------- ------------------------------------------------------------------------------------------------------------------ --------
  COPD-specific medication count             3 (2, 3)         3 (2, 3)            3 (3, 4)        3 (3, 4)                                                                                                           0.187
  Non-COPD medication count                  4 (2, 7)         6 (4, 8)            5 (3, 6)        5 (3, 8)                                                                                                           0.119
  Total medication count                     6 (4, 10)        9 (6, 11)           8 (6, 9)        8 (6, 11)                                                                                                          0.173
  MRCI score for COPD-specific medications   13.5 (9.5, 15)   12.5 (9.5, 15.5)    13 (11.5, 16)   15.5 (12.5, 19.5)[\*](#tfn15-copd-12-2929){ref-type="table-fn"},[\*\*](#tfn16-copd-12-2929){ref-type="table-fn"}   0.0001
  MRCI score for non-COPD medications        8 (3, 14)        10 (7, 16)          9 (5, 11)       9 (5, 14)                                                                                                          0.203
  MRCI score for all medications             22.5 (16, 26)    22.5 (18.5, 27.5)   21.5 (19, 25)   27 (19.5, 32.5)[\*\*\*](#tfn17-copd-12-2929){ref-type="table-fn"}                                                  0.019

**Notes:**

*P*=0.0001 versus patients in GOLD A.

*P*\<0.0001 versus patients in GOLD B.

*P*=0.004 versus patients in GOLD A.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; MRCI, medication regimen complexity index.
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![Prevalence of comorbidities by disease categories.\
**Abbreviation:** ENT, ear, nose and throat.](copd-12-2929Fig1){#f1-copd-12-2929}

![Donut chart showing the percentage contributions of dosage form, dosing frequency, and additional instructions to the total MRCI scores of COPD, non-COPD, and all medications.\
**Abbreviation:** MRCI, medication regimen complexity index.](copd-12-2929Fig2){#f2-copd-12-2929}

![Summary of medication counts and MRCI scores of COPD, non-COPD, and all medications for study population based on GOLD quadrants.\
**Notes:** \**P*=0.004 versus patients in GOLD A. ^φ^*P*=0.0001 versus patients in GOLD A. ^Ψ^*P*\<0.0001 versus patients in GOLD B. Data presented as median (*q*1, *q*3).\
**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; med, medication; MRCI, medication regimen complexity index.](copd-12-2929Fig3){#f3-copd-12-2929}

![Medication regimen complexity in relation to class of comorbidities for non-COPD medications (**A**) and COPD medications (**B**).\
**Notes:** Comorbid musculoskeletal diseases, skin disorders, and cancer are not included in the figure as they did not contribute to complex medication regimens. \**P*\<0.05.\
**Abbreviation:** MRCI, medication regimen complexity index.](copd-12-2929Fig4){#f4-copd-12-2929}

###### 

Demographics and clinical characteristics of cohort

  Characteristic                            Value (n=222)
  ----------------------------------------- --------------------
  Sex (male)                                130 (58.6%)
  Age (years)                               69.1 (8.3)
  BMI (kg/m^2^)                             30.5 (24.5, 35.4)
  Postbronchodilator FEV~1~ (% predicted)   56.5 (20.4)
  Postbronchodilator FVC (% predicted)      76.9 (17.2)
  FEV~1~/FVC ratio                          55 (16.3)
  mMRC score ≥2                             167 (75.2%)
  GOLD grades                               
   1                                        29 (13%)
   2                                        107 (48.2%)
   3                                        63 (28.4%)
   4                                        23 (10.4%)
  GOLD quadrant                             
   A                                        21 (9.5%)
   B                                        49 (22%)
   C                                        35 (15.8%)
   D                                        117 (52.7%)
  Smoking status                            
   Ex-smokers                               197 (88.7%)
   Smokers                                  6 (2.7%)
   Never smokers                            19 (8.6%)
  Pack-years                                40 (21, 62)
  CAT score (n=190)                         20.6 (6.9)
  SGRQ (n=217)                              54.1 (16)
  HADS total score (n=221)                  12 (7, 16)
  Exacerbation history                      2 (1, 3)
  6MWD meters (n=156)                       382.9 (275, 454.6)
  Current respiratory medication use        
   SABA                                     206 (92.8%)
   LABA                                     28 (12.6%)
   SAMA                                     11 (5%)
   LAMA                                     194 (87.4%)
   Theophylline                             4 (1.8%)
   ICS                                      24 (10.8%)
   ICS/LABA combination                     179 (81%)
   OCS                                      3 (1.4%)
   LTRA                                     2 (0.9%)
   Oxygen                                   19 (8.6%)
   Nasal steroids                           8 (3.6%)
  Indices                                   
  Comorbidity-specific indices              
   CCI                                      4 (3, 5)
   COTE (n=150)                             1 (0, 3)
   CODEx                                    3 (2, 5)
  Multidimensional indices                  
   BODE (n=156)                             3 (1, 5)
   BODEx                                    3 (2, 5)
   ADO                                      4.7 (1.7)
   DOSE                                     2.7 (1.6)

**Note:** Data presented as n (%), mean (SD), or median (interquartile range \[*q*1, *q*3\]).

**Abbreviations:** ADO, age, dyspnea and airflow obstruction; BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea and exercise capacity; BODEx, body mass index, airflow obstruction, dyspnea and severe exacerbation; CAT, COPD assessment test; CCI, Charlson Comorbidity Index; CODEx, comorbidity, airway obstruction, dyspnea and severe exacerbation; COTE, comorbidity test; DOSE, dyspnea, airflow obstruction, smoking status and exacerbation; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, hospital anxiety and depression scale; ICS, inhaled corticosteroids; LABA, long-acting beta~2~ agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; 6MWD, 6-minute walk distance; mMRC, modified Medical Research Council; OCS, oral corticosteroids; SABA, short-acting beta agonist; SAMA, short-acting muscarinic antagonist; SGRQ, St George's Respiratory Questionnaire.

###### 

Summary of MRCI and medication count for study population

  Measures                             All medications   COPD medications    Non-COPD medications   *P*-value[\*](#tfn4-copd-12-2929){ref-type="table-fn"}
  ------------------------------------ ----------------- ------------------- ---------------------- --------------------------------------------------------
  Total number of medications          8 (6, 11)         3 (3, 4)            5 (3, 8)               \<0.0001
  MRCI section A score (dosage form)   11 (8, 12)        9 (7, 10)           2 (1, 3)               \<0.0001
  MRCI section B score (frequency)     10 (7.5, 14.5)    3.5 (3.5, 5.5)      6 (3.5, 9)             \<0.0001
  MRCI section C score (direction)     3 (2, 5)          2 (1, 2)            1 (0, 3)               0.0188
  Total MRCI score                     24 (18.5, 31)     14.5 (11.5, 17.5)   9 (5.5, 15)            \<0.0001

**Notes:** Data presented as median (*q*1, *q*3).

*P*-value for the comparison of COPD and non-COPD medications.

**Abbreviation:** MRCI, medication regimen complexity index.

###### 

Correlations between clinical outcomes and medication burden

  Clinical outcomes                         Total MRCI score for all medications   Total medication counts   COPD-specific medications MRCI score   COPD-specific medication count
  ----------------------------------------- -------------------------------------- ------------------------- -------------------------------------- --------------------------------
  CAT score                                 *ρ*=0.211; *P*=0.0034                  *ρ*=0.132; *P*=0.0697     *ρ*=0.200; *P*=0.0056                  *ρ*=0.195; *P*=0.0070
  SGRQ                                      *ρ*=0.301; *P*\<0.0001                 *ρ*=0.235; *P*=0.0005     *ρ*=0.294; *P*\<0.0001                 *ρ*=0.299; *P*\<0.0001
  Postbronchodilator FEV~1~ (% predicted)   *ρ*=−0.106; *P*=0.1141                 *ρ*=0.071; *P*=0.2907     *ρ*=−0.393; *P*\<0.0001                *ρ*=−0.408; *P*\<0.0001
  Prior year exacerbation history           *ρ*=0.213; *P*=0.0014                  *ρ*=0.133; *P*=0.0486     *ρ*=0.246; *P*=0.0002                  *ρ*=0.276; *P*\<0.0001
  Prior year hospitalization history        *ρ*=0.109; *P*=0.1043                  *ρ*=0.095; *P*=0.1583     *ρ*=0.151; *P*=0.0249                  *ρ*=0.130; *P*=0.0528
  6MWD                                      *ρ*=−0.369; *P*\<0.0001                *ρ*=−0.302; *P*\<0.0001   *ρ*=−0.288; *P*=0.0003                 *ρ*=−0.259; *P*=0.0011

**Abbreviations:** CAT, COPD assessment test; FEV~1~, forced expiratory volume in 1 second; 6MWD, 6-minute walk distance; MRCI, medication regimen complexity index; SGRQ, St George's Respiratory Questionnaire.

###### 

Total medication counts and MRCI scores for all medications in patients with and without comorbidities

  Comorbidity                 Total MRCI score    *P*-value   Total medication count   *P*-value
  --------------------------- ------------------- ----------- ------------------------ -----------
  Cardiovascular diseases     \<0.0001                        \<0.0001                 
   Yes                        26.8 (20.5, 33.5)               10 (7, 12)               
   No                         20.3 (16.5, 24.5)               6 (5, 8)                 
  Gastrointestinal diseases   0.0024                          0.0001                   
   Yes                        25.5 (20.0, 32.0)               9 (7, 12)                
   No                         22.0 (17.5, 28.5)               7 (5, 10)                
  Musculoskeletal diseases    0.4297                          0.0189                   
   Yes                        24.5 (18.5, 31.0)               9 (7, 11)                
   No                         23.5 (18.5, 31.0)               7 (6, 11)                
  Metabolic disorder          0.0001                          \<0.0001                 
   Yes                        27.4 (9.2)                      10 (7, 12)               
   No                         22.8 (7.9)                      7 (5, 9)                 
  Respiratory diseases        0.0007                          0.0001                   
   Yes                        25.5 (20.5, 33.0)               9 (7, 12)                
   No                         21.5 (17.5, 28.0)               7 (5, 10)                
  Psychiatric disorders       0.0013                          0.0030                   
   Yes                        27.5 (9.5)                      9 (7, 13)                
   No                         23.6 (8.1)                      8 (6, 10)                
  Skin disorders              0.2993                          0.0298                   
   Yes                        24.5 (19.5, 31.5)               9 (7, 13)                
   No                         23.5 (18.5, 29.5)               8 (6, 11)                
  Neurological condition      0.0489                          0.0465                   
   Yes                        24.5 (20.0, 34.0)               9 (7, 13)                
   No                         23.5 (18.5, 29.5)               8 (6, 11)                
  Cancer                      0.5923                          0.6091                   
   Yes                        24.3 (17.5, 32.0)               9 (6, 12)                
   No                         23.5 (19, 30.3)                 8 (6, 11)                

**Note:** Data presented as mean (SD) or median (*q*1, *q*3).

**Abbreviation:** MRCI, medication regimen complexity index.

###### 

Results of multiple regression analysis for comorbidities that contributed to higher medication count

  Model                        Coefficient   *t*      Significance   95% confidence interval
  ---------------------------- ------------- -------- -------------- -------------------------
  Constant                     5.284         11.500   \<0.0001       (4.378, 6.190)
  Cardiovascular diseases      2.381         4.590    \<0.0001       (1.360, 3.403)
  Gastrointestinal diseases    0.927         2.000    0.047          (0.014, 1.841)
  Musculoskeletal diseases     0.149         0.340    0.737          (−0.725, 1.024)
  Metabolic disorder           1.003         2.110    0.036          (0.068, 1.939)
  Other respiratory diseases   0.621         1.370    0.171          (−0.270, 1.512)
  Psychiatric disorders        0.681         1.500    0.134          (−0.211, 1.574)
  Skin disorders               0.376         0.800    0.425          (−0.551, 1.303)
  Neurological conditions      0.912         1.710    0.089          (−0.140, 1.964)

**Notes:** The proportion of the variance explained by the model (*R*^2^) was 0.29; *P*\<0.0001.

###### 

Results of multiple regression analysis for comorbidities that contributed to greater complexity of medication regimen

  Model                        Coefficient   *t*    Significance   95% confidence interval
  ---------------------------- ------------- ------ -------------- -------------------------
  Constant                     15.015        3.04   0.003          (5.288, 24.743)
  Cardiovascular diseases      3.225         2.39   0.018          (0.565, 5.885)
  Gastrointestinal diseases    1.725         1.48   0.139          (−0.565, 4.016)
  Metabolic disorder           2.403         1.96   0.051          (−0.010, 4.817)
  Other respiratory diseases   1.924         1.63   0.105          (−0.406, 4.254)
  Psychiatric disorders        1.997         1.66   0.099          (−0.376, 4.369)
  Neurological conditions      2.452         1.78   0.076          (−0.259, 5.162)

**Notes:** The proportion of the variance explained by the model (*R*^2^) was 0.18; *P*\<0.0001.

###### 

Association of medication burden with comorbidity specific and multidimensional indices in COPD

  Indices                        Total MRCI score for all medications   Total medication count
  ------------------------------ -------------------------------------- ------------------------
  Comorbidity-specific indices                                          
   CCI                           *ρ*=0.289; *P*\<0.0001                 *ρ*=0.359; *P*\<0.0001
   COTE                          *ρ*=0.326; *P*\<0.0001                 *ρ*=0.316; *P*=0.0001
   CODEx                         *ρ*=0.269; *P*\<0.0001                 *ρ*=0.152; *P*=0.0240
  Multidimensional indices                                              
   BODE                          *ρ*=0.181; *P*=0.0237                  *ρ*=0.064; *P*=0.4257
   BODEx                         *ρ*=0.198; *P*=0.0030                  *ρ*=0.061; *P*=0.3668
   DOSE                          *ρ*=0.235; *P*=0.0004                  *ρ*=0.111; *P*=0.0988
   ADO                           *ρ*=0.188; *P*=0.0049                  *ρ*=0.131; *P*=0.0509

**Abbreviations:** ADO, age, dyspnea and airflow obstruction; BODE, body mass index, airflow obstruction, dyspnea and exercise capacity; BODEx, body mass index, airflow obstruction, dyspnea and severe exacerbation; CCI, Charlson Comorbidity Index; CODEx, comorbidity, airway obstruction, dyspnea and previous severe exacerbation; COTE, comorbidity test; DOSE, dyspnea, airflow obstruction, smoking status and exacerbation; MRCI, medication regimen complexity index.
